Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy
Retrospective study reveals CLL treatment patterns with zanubrutinib post-ibrutinib therapy, suggesting good tolerability.
Key Points
This study aimed to evaluate the real-world treatment patterns of zanubrutinib in patients with chronic lymphocytic leukemia after previous BTKi therapy.
Retrospective analysis of electronic medical records from Florida Cancer Specialists & Research Institute
Patients identified using ICD-10 codes with previous treatments of ibrutinib or acalabrutinib
Evaluation of treatment-related adverse events and treatment discontinuation reasons.
Of patients receiving zanubrutinib, 54% were switched from ibrutinib and 46% from acalabrutinib
68.5% switched from ibrutinib primarily due to treatment-related adverse events
60% of patients continued treatment with zanubrutinib throughout the study period.